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Abstract
Background: Vitiligo is an acquired depigmenting disorder due to destruction of melanocytes. Although
many theories have been suggested for its pathogenesis, the role of autoimmunity is the most popular one.
The association of vitiligo with autoimmune thyroid diseases and the increased prevalence of
autoantibodies including thyroid autoantibodies in vitiligo favor this role. Our objective was to compare
the frequency of thyroid peroxidase antibody (anti-TPO) in vitiligo patients with healthy subjects in Iran.
Methods: Ninety-four cases of vitiligo (46 female and 48 male) and 96 control subjects (49 female and 47
male) were enrolled in this controlled study. Patients with known thyroid disease, history of thyroid
surgery and those receiving thyroid medications were not included. The two groups were matched
regarding gender and age. The demographic data, symptoms related to thyroid diseases and results of skin
and thyroid examinations were recorded in a questionnaire for each subject. Thyroid function tests
including free T3, free T4 and TSH-IRMA were performed. Anti-TPO levels were assessed as well. The
collected data were analyzed by SPSS version-11 in vitiligo patients and subgroups according to gender,
age, extent, and duration of the disease compared with the control group.
Results: Anti-TPO was detected in 17 (18.1%) of patients affected by vitiligo, while this figure was 7 (7.3%)
in the control group; the difference was significant with p-value < 0.025 (Phi & Cramer's V = 0.162). When
analyzing subgroups, the difference in the frequency of anti-TPO remained significant only in females (p-
value < 0.044) (Phi & Cramer's V = 0.207) and in patients in the age ranges of 18–25 (p-value < 0.05) (Phi
& Cramer's V = 0.28) and 26–35 year-old (p-value < 0.042) (Phi & Cramer's V = 0.304).
The difference of the frequency of anti-TPO was not significant regarding the duration and extent of
vitiligo. In addition, there was no significant difference in the levels of free T3, free T4, and TSH in vitiligo
patients compared with the control group.
Conclusion: According to our study, anti-TPO was shown to be significantly more common in vitiligo
patients especially in young women, compared with control group. As this antibody is a relatively sensitive
and specific marker of autoimmune thyroid disorders including Hashimoto thyroiditis and Graves' disease,
and considering the fact that vitiligo usually precedes the onset of thyroid dysfunction, periodic follow-up
of vitiligo patients for detecting thyroid diseases is further emphasized especially in young women with
increased level of anti-TPO.
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Background
Vitiligo is an acquired depigmenting disorder due to
destruction of melanocytes and the resultant absence of
pigment production affecting skin and mucosal surfaces
with a prevalence of about 1%. Different theories regard-
ing its pathogenesis have been put forward, autoimmu-
nity being the most popular one. The latter is based
mainly on the association of vitiligo with known autoim-
mune diseases and the presence of organ specific antibod-
ies in affected patients [1]. Thyroid functional disorders
and autoimmune thyroid diseases have been reported in
association with vitiligo and it seems that the incidence of
clinical and subclinical thyroid involvement is more com-
mon in vitiligo patients than healthy subjects [2]. Vitiligo
frequently precedes the thyroid involvement; thus screen-
ing vitiligo patients for thyroid function and thyroid anti-
body seems plausible [3]. Moreover, increased risk of
autoimmune/endocrine diseases was shown in first and
second degree relatives of vitiligo patients with positive
organ specific antibodies [4]. Hashimoto thyroiditis and
Graves' disease are the most important and prevalent
autoimmune thyroid diseases associated with vitiligo. Ele-
vated levels of anti-TPO are seen in more than 90% cases
of Hashimoto thyroiditis and about 75% of Graves' dis-
ease cases. This figure is only 10% in healthy people
although it may reach 30% in the elderly [5,6]. In this
study, we assessed the frequency of anti-TPO as a sensitive
marker of autoimmune diseases of the thyroid in vitiligo
patients and compared it with healthy subjects in order to
find data further supporting the autoimmune theory in
the pathogenesis of vitiligo.
Methods
We conducted this controlled study for comparison of
anti-TPO in vitiligo and healthy subjects in Razi Hospital,
a university hospital in Tehran, Iran, from September
2004 till March 2005. Ninety-four vitiligo (46 females, 48
males) patients without a history of thyroid surgery or tak-
ing medication for thyroid diseases were enrolled. The
control group (96 cases; 49 females, 47 males) comprised
healthy medical students, medical staff and outpatients'
relatives; cases with any history or sign of vitiligo and pos-
itive family history of vitiligo in their first and second
degree relatives as well as those with a history of thyroid
surgery or taking medication for thyroid diseases were
excluded. All the subjects in the two groups underwent a
complete skin and thyroid examination. The thyroid func-
tion tests (Free T4, Free T3, and TSH) and anti-TPO were
assessed for all. Radio-immunoassay was used for thyroid
function tests (Kits for Free T3 and Free T4: Monobind;
TSH: Immunotech). Anti-TPO was assessed using enzyme
linked immunosorbant assay (ELISA) (Kit from Monob-
ind) (Normal range: up to 40 IU/ml). The study was
approved by the Committee of Ethics of the vice -chancel-
lor of Tehran University of Medical Sciences. Consent was
obtained from all participants. The data were analyzed
using SPSS software version 11 with Mann-Whitney U, t,
chi-square, Fisher's exact, Kolmogorov-Smirnov and Phi &
Cramer's V tests.
Results
Some of the demographic and clinical findings of vitiligo
patients are presented in table 1. The mean ages were
28.67 year old (SD = 15.42) and 27.64 year old (SD =
13.7) in the case and control groups, respectively. Thyroid
size was normal in 80% (76 cases) of study group versus
83% (73 cases) in control group. The thyroid size was in
stage I in 17.9% (17 cases) and 15.9% (14 cases) in the
study and case groups, respectively. Two cases (2.1%) of
the case group and one case (1.1%) of the control group
had stage II thyroid size. The difference of thyroid size was
not significant between the two groups (chi-square p =
0.81). The FT3 and FT4 were reported in normal range in
93.6% and 94.7% of study group, and 99% and 96.9% of
control group, respectively (FT3 normal range: 1.5–5 pg/
ml; FT4 normal range: 0.6–2.6 ng/ml). No significant dif-
ference was detected in this regard between the two
groups (chi-square p > 0.01). TSH level was significantly
higher in the study group than the control one, 1.59 mIU/
ml (SD = 1.25) versus 1.14 mIU/ml (SD = 1.48), respec-
tively (Mann-Whitney, p = 0.001) but there was no signif-
icant difference between the frequency of normal TSH
between the two groups [92.6% versus 86.5% (chi-square
p = 0.355)] (TSH normal range: 0.2–5 mIU/ml).
Table 1: Clinical characteristics of vitiligo patients
Mean age +/- SD (year) 28.67+/-15.42
Age range 4–83
Gender (female:male) 63:31 (2:1)
Age (year)
=>17 22 (23.4)
18–25 24 (25.5)
26–35 27 (28.7)
=<36 21 (22.3)
Mean age of onset +/- SD (year) 22.86+/-15.37
Age of onset range(year) 2–82
Mean duration +/- SD (year) 5.85+/-7.55
Duration Range (year) 0–40
Extent (%)
<20 70 (74.5)
20–50 20 (21.3)
>50 3 (3.2)
Type of vitiligo, n (%)
Generalized 63 (67)
Focal 17 (18.1)
Acrofacial 5 (5.3)
Mucosal 2 (2.1)
Segmental 1 (1.1)
Lip-tip 1 (1.1)
Universalis 1 (1.1)
Unclassified 4 (4.3)BMC Dermatology 2006, 6:3 http://www.biomedcentral.com/1471-5945/6/3
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Anti-TPO was detected in seventeen cases (18.1%) in vitil-
igo patients compared with 7 cases (7.3%) in the control
group: The difference was statistically significant with a p-
value of 0.025. The intensity of the association of the pres-
ence of anti-TPO with vitiligo was 16.2% (Phi & Cramer's
V = 0.162). Five cases (10.4%) of males in the vitiligo
group were anti-TPO positive while this figure was 2
(4.3%) in the control group with no significant difference
(Fisher's exact test: p = 0.226). Twelve female cases
(26.1%) in the study group had anti-TPO compared to 5
cases (10.2%) in the control group. There was a significant
difference in anti-TPO positivity in female cases between
the study and control groups (chi-square = 0.044)  ( Phi &
Cramer's V = 0.207). In order to assess the variation of
anti-TPO with age, each group was divided into four equal
subgroups: lower or equal to 17 year old, between 18 and
25, between 26 and 35 and equal or greater than 36 year-
old. In the age range of 18 to 25, 20.8% of the study group
and 3.2% of the control subjects had positive anti-TPO
results showing a significant difference (Fisher's exact test:
p< 0.05) ( Phi & Cramer's V = 0.28). Likewise, 18.5% of
vitiligo patients in the age range of 26 to 35 versus 0% of
controls showed positive anti-TPO with a significant dif-
ference (Fisher's exact test = 0.042) ( Phi & Cramer's V =
0.304). No significant difference was noted in the two
other age ranges. Furthermore the frequency of positive
anti-TPO showed no significant difference regarding the
extent of the disease, the age of onset, the mean duration
of disease and its clinical manifestations (including gener-
alized versus non-generalized). Demographic and clinical
findings of vitiligo patients with and without anti-TPO are
presented in table 2. As only one patient suffered from
segmental vitiligo, comparison of segmental and non-seg-
mental vitiligo was not valuable. None of the patients
were known cases of other autoimmune diseases.
Clinical autoimmune thyroid disease was diagnosed sub-
sequent to positive anti-TPO results in 4 out of 24 (17%),
2 in the case and 2 in the control group. There were one
case of autoimmune thyroiditis (45-year-old woman,
anti-TPO positive), one case of Graves' disease (19-year-
old woman, anti-TPO positive) and a case of subclinical
hypothyroidism (29-year-old man, anti-TPO negative) in
the vitiligo group and two patients with Hashimoto thy-
roiditis (41-year-old woman and 12-year-old boy, both
anti-TPO positive), one case of transient thyroiditis (30-
year-old man, anti-TPO negative) and one patient with
subclinical hypothyroidism (33-year-old man, anti-TPO
negative) in the control group.
Discussion
Vitiligo is a generalized autoimmune disease manifesting
acquired white patches due to loss of melanocytes. It is the
most prevalent pigmentary disorder with an incidence
rate between 0.1–2% showing multifactorial etiology and
polygenic inheritance [7]. The exact etiology and patho-
genesis of this disease is not clear. Many theories have
been put forward in this regard, autoimmune theory is the
most popular one. Increased prevalence of autoimmune
disorders in association with vitiligo, detection of various
autoantibodies including anti-thyroid and anti-melano-
cyte antibodies in the serum of vitiligo patients and alter-
ation of T-cell population showing decreased T-helper
cells are in favor of this role [1].
Table 2: Comparison of clinical features of vitiligo patients with and without anti-thyroid peroxidase antibody
Clinical features No. (%) with autoantibodies (17 patients) No. (%) without autoantibodies (77 patients)
Mean age +/- SD, yr 26.47 +/-11.52 29.16 +/- 16.18
Gender
Male 5 (10.4) 43 (89.6)
Female* 12 (26.1) 34 (73.9)
Age (year)
=>17 4 (18.2) 18 (81.8)
18–25* 5 (20.8) 19 (79.2)
26–35* 5 (18.5) 22 (81.5)
=<36 3 (14.3) 18 (85.7)
Mean onset age +/- SD,yr 19.59 +/- 9.5 23.59 +/-16.36
Mean duration +/- SD,yr 6.88 +/- 9.9 5.62 +/- 6.98
Extent (%)
<20 12 (17) 58 (83)
20–50 5 (25) 15 (75)
>50 0 3 (100)
Type of vitiligo
Generalized 13 (20.6) 50 (79.4)
Non-generalized 4 (12.9) 27 (87.1)
*Difference significant compared with the control group (pv < 0.05)BMC Dermatology 2006, 6:3 http://www.biomedcentral.com/1471-5945/6/3
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Various thyroid autoantibodies including thyroid stimu-
lating antibody, anti- thyroglobulin antibody and anti-
thyroid peroxidase antibody, are detectable in autoim-
mune thyroid diseases the latter being the most sensitive
test for the diagnosis and follow-up of this group of dis-
eases. Thyroid peroxidase is responsible for the iodination
of tyrosine residues in the thyroglobulin molecule. Anti-
TPO antibody has been shown to mediate thyroid cell
destruction in vitro. This antibody, historically referred to
as the anti-microsomal antibody, is established as a sensi-
tive tool for the detection of early subclinical autoim-
mune thyroid diseases, follow up of the response to
immunotherapy and identification of at-risk cases for
autoimmune thyroid diseases [8].
Clinical as well as functional abnormalities of the thyroid
gland have been reported by many authors to be signifi-
cantly more frequent in vitiligo patients compared with
control group [2,4]. We didn't find any significant differ-
ence in thyroid size and thyroid function test results
between the case and control groups, although the plasma
level of TSH was significantly higher in vitiligo patients
but this increase remained in the normal range. This dif-
ference may be due to the lower mean age of patients in
our study since older cases are shown to be more at risk of
evolution toward subclinical thyroid diseases,[9]
although Iacovelli and his colleagues found a significant
frequency of thyroid diseases in children with non-seg-
mental vitiligo [10].
According to our study the rate of positive anti-TPO was
significantly higher in vitiligo patients compared with
control subjects. Mandry et al assessed the presence and
frequency of organ specific antibody in 20 patients with
vitiligo and their relatives. They detected anti-microsomal
and anti-thyroglobulin antibodies in 50% and 40% of
their cases, respectively; they showed increased prevalence
of organ specific antibodies in the relatives, as well [9].
Morgan et al also found higher prevalence of thyroid anti-
bodies in vitiligo patients, especially in generalized vitil-
igo, compared with healthy people [11]. Dave et al
showed antibody positivity (anti-thyroglobulin, anti-
TPO) in 31.4% of their cases in India against 10% of their
controls [12]. Grimes, Korkij, and Betterle also showed
high frequency of antithyroid antibodies [4,13,14].
Kurtev and Dourmishev reported anti-microsomal anti-
bodies in 50% of their cases with vitiligo (children and
adolescents) [15]. Iacovelli et al reported a figure of 7% in
children with non-segmental vitiligo, especially in
females, all of them had thyroid dysfunction [10].
According to our study, the difference in the prevalence of
anti-TPO was significant only in female cases and patients
in the age ranges of 18 to 35 year-old, findings not previ-
ously reported in the literature. In our study we found no
relationship between the presence of anti-TPO antibodies
and the extent, duration, age of onset and anatomical
location. Morgan found autoantibodies especially in gen-
eralized vitiligo [11], Mandry in patients with later onset
of the disease and a higher mean age [9], Betterle in
patients with long lasting vitiligo,[14] and Dave in
patients with mucosal and early onset vitiligo [12]. Fur-
ther studies with larger sample size are suggested to eluci-
date these issues in the future.
Conclusion
According to our study, anti-TPO was shown to be signif-
icantly more common in vitiligo patients especially in
young women, compared with control group. As this anti-
body is a sensitive tool for the detection of autoimmune
thyroid disorders including Graves' disease and Hashim-
oto thyroiditis, and considering the fact that vitiligo usu-
ally precedes the onset of thyroid dysfunction, periodic
follow-up of vitiligo patients for detecting thyroid dis-
eases is further emphasized especially in young women
with increased level of anti-TPO.
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